86Y based PET radiopharmaceuticals: Radiochemistry and biological applications

Medicinal Chemistry

Volumn 7, Issue 5, 2011, Pages 380-388

  Nayak, Tapan K ^a   Brechbiel, Martin W ^b  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

86Y; 90Y; And antibodies; Bioconjugate chemistry; Peptides; PET imaging; Radiochemistry

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID OCTREOTIDE[1 DEXTRO PHENYLALANINE 3 TYROSINE] YTTRIUM 90; BEVACIZUMAB; CETUXIMAB; IBRITUMOMAB TIUXETAN; OCTREOTIDE; PANITUMUMAB; PENTETIC ACID; UNCLASSIFIED DRUG; YTTRIUM 86; YTTRIUM 90; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT; YTTRIUM;

DOSIMETRY; DRUG HALF LIFE; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION DOSE; RADIOCHEMISTRY; RADIOISOTOPE THERAPY; REVIEW; TREATMENT PLANNING; ANIMAL; CHEMISTRY; NEOPLASM;

ANIMALS; HUMANS; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOCHEMISTRY; RADIOPHARMACEUTICALS; YTTRIUM RADIOISOTOPES;

EID: 80051975594     PISSN: 15734064     EISSN: 18756638     Source Type: Journal    
DOI: 10.2174/157340611796799249     Document Type: Review

References (59)

1. Krenning, E. P.; Kwekkeboom, D. J.; Valkema, R.; Pauwels, S.; Kvols, L. K.; De Jong, M. Peptide receptor radionuclide therapy. Ann. NY Acad. Sci., 2004, 1014, 234-245. (Pubitemid 38594811)
2. Sharkey, R. M.; Goldenberg, D. M.; Advances in radioimmunotherapy in the age of molecular engineering and pretargeting. Cancer Invest., 2006, 24, 82-97. (Pubitemid 43250654)
3. 90Y-ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large b-cell lymphoma patients. Clin. Cancer Res., 2010, 16, 3998-4004.
4. 90Y-linked monoclonal muc-1 antibodies. Crit. Rev. Oncol. Hematol., 2001, 38, 25-35. (Pubitemid 32194592)
5. 90Y-dota-anti-cea chimeric t84.66 (ct84.66) radioimmunotherapy in patients with metastatic cea-producing malignancies. Cancer Biother. Radiopharm., 2006, 21, 88-100. (Pubitemid 43830430)
6. 90Y-dotatoc) in neuroendocrine tumours. Eur. J. Nucl. Med. Mol. Imag., 2004, 31, 1038-1046. (Pubitemid 38915663)
7. 90Y-zevalin (Yttrium-90 ibritumomab tiuxetan, idec-y2b8) radioimmunotherapy dosimetry results in relapsed or refractory non-hodgkin's lymphoma. Eur. J. Nucl. Med., 2000, 27, 766-777. (Pubitemid 30456759)
8. 177Lu-dotatate: The role of associated risk factors. Eur. J. Nucl. Med. Mol. Imag., 2008, 35, 1847-1856.
9. Mansberg, R.; Sorensen, N.; Mansberg, V.; Van der Wall, H. Yttrium-90 bremsstrahlung spect/ct scan demonstrating areas of tracer/tumour uptake. Eur. J. Nucl. Med. Mol. Imag. 2007, 34, 1887. (Pubitemid 47599065)
10. Shen, S.; DeNardo, G. L.; DeNardo S. J. Quantitative bremsstrahlung imaging of Yttrium-90 using a wiener filter. Med. Phys., 1994, 21, 1409-1417. (Pubitemid 24307958)
11. 111Inpentetreotide in patients with advanced neuroendocrine tumours. Eur. J. Nucl. Med. Mol. Imag., 2004, 31, 1386-1392. (Pubitemid 39361934)
12. 90Y-labeled monoclonal antibodies in xenograft-bearing nude mice. J. Nucl. Med., 2003, 44, 1663-1670. (Pubitemid 40003744)
13. 111In radiolabels. J. Nucl. Med., 2001, 42, 1281-1287. (Pubitemid 32717850)
14. 90Y-2it-bad-m170 for metastatic prostate cancer. Clin. Cancer Res., 2001, 7, 1561-1568. (Pubitemid 32708620)
15. 86Y-dota0)-d-phe1-tyr3- octreotide (smt487)-a phase 1 clinical study: Pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion. Eur. J. Nucl. Med. Mol. Imag., 2003, 30, 510-518. (Pubitemid 36559829)
16. 86Y for quantitative PET of carcinoma. J. Nucl. Med., 2010, 51, 942-950.
17. 86Y-chx-a"-dtpa-bevacizumab. Int. J. Cancer, 2011, 128, 920-926.
18. 90Y-labelled analogue. Eur. J. Nucl. Med., 1999, 26, 358-366. (Pubitemid 29176446)
19. Qaim, S. M. Decay data and production yields of some nonstandard positron emitters used in PET. Q. J. Nucl. Med. Mol. Imag., 2008, 52, 111-120. (Pubitemid 351721930)
20. Herzog, H.; Rosch, F.; Stocklin, G.; Lueders, C.; Qaim, S. M.; Feinendegen, L. E. Measurement of pharmacokinetics of Yttrium-86 radiopharmaceuticals with pet and radiation dose calculation of analogous Yttrium-90 radiotherapeutics. J. Nucl. Med., 1993, 34, 2222-2226. (Pubitemid 24002971)
21. Yoo, J.; Tang, L.; Perkins, T. A.; Rowland, D. J.; Laforest, R.; Lewis, J. S.; Welch, M. J. Preparation of high specific activity 86Y using a small biomedical cyclotron. Nucl. Med. Biol. 2005, 32, 891-897. (Pubitemid 41505323)
22. 111In labeled herceptin. Nucl. Med. Biol. 2002, 29, 599-606. (Pubitemid 34667122)
23. 86Y using a small biomedical cyclotron. Nucl. Med. Biol., 2005, 32, 891-897. (Pubitemid 41505323)
24. 86Sr targets. Appl. Radiat. Isot. 2008, 66, 9-13. (Pubitemid 350087675)
25. 90Y radioimmunotherapy. Bioconjugate Chem., 1991, 2, 187-194.
26. Roselli, M.; Schlom, J.; Gansow, O. A.; Raubitschek, A.; Mirzadeh, S.; Brechbiel, M. W.; Colcher, D. Comparative biodistributions of yttrium-and indium-labeled monoclonal antibody b72.3 in athymic mice bearing human colon carcinoma xenografts. J. Nucl. Med., 1989, 30, 672-682. (Pubitemid 19140261)
27. Camera, L.; Kinuya, S.; Garmestani, K.; Brechbiel, M. W.; Wu, C.; Pai, L. H.; McMurry, T. J.; Gansow, O. A.; Pastan, I.; Paik, C. H.; et al.: Comparative biodistribution of indium-and yttrium-labeled b3 monoclonal antibody conjugated to either 2-(p-scn-bz)-6-methyl-dtpa (1b4m-dtpa) or 2-(p-scn-bz)-1, 4, 7, 10-tetraazacyclododecane tetraacetic acid (2b-dota). Eur. J. Nucl. Med., 1994, 21, 640-646. (Pubitemid 24211116)
28. Camera, L.; Kinuya, S.; Garmestani, K.; Wu, C.; Brechbiel, M. W.; Pai, L. H.; McMurry, T. J.; Gansow, O. A.; Pastan, I.; Paik, C. H.; et al.: Evaluation of the serum stability and in vivo biodistribution of chx-dtpa and other ligands for yttrium labeling of monoclonal antibodies. J. Nucl. Med., 1994, 35, 882-889. (Pubitemid 24151230)
29. 111In-labeled b3 monoclonal antibody in athymic mice bearing human epidermoid carcinoma xenografts. Nucl. Med. Biol., 1993, 20, 955-962. (Pubitemid 23338079)
30. Kobayashi, H.; Wu, C.; Yoo, T. M.; Sun, B. F.; Drumm, D.; Pastan, I.; Paik, C. H.; Gansow, O. A.; Carrasquillo, J. A.; Brechbiel, M. W: Evaluation of the in vivo biodistribution of yttrium-labeled isomers of chx-dtpa-conjugated monoclonal antibodies. J. Nucl. Med., 1998, 39, 829-836. (Pubitemid 28216733)
31. Clifford, T.; Boswell, C. A.; Biddlecombe, G. B.; Lewis, J. S.; Brechbiel, M. W. Validation of a novel chx-a" derivative suitable for peptide conjugation: Small animal pet/ct imaging using Yttrium-86-chx-a"- octreotide. J. Med. Chem., 2006, 49, 4297-4304. (Pubitemid 44036673)
32. Deshpande, S. V.; DeNardo, S. J.; Kukis, D. L.; Moi, M. K.; McCall, M. J.; DeNardo, G. L.; Meares, C. F. Yttrium-90-labeled monoclonal antibody for therapy: Labeling by a new macrocyclic bifunctional chelating agent. J. Nucl. Med., 1990, 31, 473-479. (Pubitemid 20144715)
33. 90Y from cyclic and acyclic ligand-antibody conjugates. Int. J. Radiat. Appl. Instrum., B 1991, 18, 469-476.
34. de Jong, M.; Bakker, W. H.; Krenning, E. P.; Breeman, W. A.; van der Pluijm, M. E.; Bernard, B. F.; Visser, T. J.; Jermann, E.; Behe, M.; Powell, P.; Macke, H. R. Yttrium-90 and Indium-111 labelling, receptor binding and biodistribution of [dota0, dphe1, tyr3]octreotide, a promising somatostatin analogue for radionuclide therapy. Eur. J. Nucl. Med., 1997, 24, 368-371. (Pubitemid 27183039)
35. 90Y dosimetry in an ovarian carcinoma model: Correlative micropet and mri. J. Nucl. Med., 2003, 44, 1148-1155. (Pubitemid 39663389)
36. Brechbiel, M. W: Bifunctional chelates for metal nuclides. Q. J. Nucl. Med. Mol. Imag., 2008, 52, 166-173.
37. 86Y-dotareccmsh (arg11), a cyclized peptide analogue of alpha-msh. J. Med. Chem., 2005, 48, 2985-2992. (Pubitemid 40548110)
38. 86Y-dota- (pro1, tyr4)-bombesin (1-14). Bioconjugate Chem., 2007, 18, 724-730. (Pubitemid 47010791)
39. 68Ga-labeled chx-a"-re (arg11) ccmsh. Nucl. Med. Biol., 2009, 36, 345-354.
40. 90Y-radiolabeled anti-lewis y humanized monoclonal antibody hu3s193 and paclitaxel combined-modality radioimmunotherapy in a breast cancer model. J. Nucl. Med., 2006, 47, 716-725. (Pubitemid 46768474)
41. 90Y-labeled anti-cd20 monoclonal antibody. Clin. Cancer Res., 1999, 5, 3281s-3286s. (Pubitemid 29493928)
42. 177Lu-labeled j591 monoclonal antibodies: Effect of multiple treatments on myelotoxicity. Clin. Cancer Res., 2005, 11, 7195s-7200s. (Pubitemid 41428723)
43. Boswell, C. A.; Brechbiel, M. W: Development of radioimmunotherapeutic and diagnostic antibodies: An inside-out view. Nucl. Med. Biol., 2007, 34, 757-778. (Pubitemid 47503817)
44. Nayak, T. K.; Brechbiel, M. W: Radioimmunoimaging with longerlived positron-emitting radionuclides: Potentials and challenges. Bioconjugate Chem., 2009, 20, 825-841.
45. Milenic, D. E.; Wong, K. J.; Baidoo, K. E.; Nayak, T. K.; Regino, C. A.; Garmestani, K.; Brechbiel, M. W. Targeting her2: A report on the in vitro and in vivo pre-clinical data supporting trastuzumab as a radioimmunoconjugate for clinical trials. MAbs., 2010, 2, 550-564.
46. 86Y-chx-a"-dtpa-cetuximab. Eur. J. Nucl. Med. Mol. Imag., 2010, 37, 1368-1376.
47. Parry, R.; Schneider, D.; Hudson, D.; Parkes, D.; Xuan, J.A.; Newton, A.; Toy, P.; Lin, R.; Harkins, R.; Alicke, B.; Biroc, S.; Kretschmer, P. J.; Halks-Miller, M.; Klocker, H.; Zhu, Y.; Larsen, B.; Cobb, R. R.; Bringmann, P.; Roth, G.; Lewis, J. S.; Dinter, H.; Parry, G. Identification of a novel prostate tumor target, mindin/rg-1, for antibody-based radiotherapy of prostate cancer. Cancer Res., 2005, 65, 8397-8405. (Pubitemid 41330606)
48. 111In-antimindin/rg-1, engineered antibody fragments in lncap tumor-bearing nude mice. J. Nucl. Med., 2009, 50, 435-443.
49. 86Y-labeled mirror-image oligonucleotide: Influence of Y-DOTA isomers on the biodistribution in rats. Bioconjugate Chem., 2008, 19, 928-939. (Pubitemid 351614547)
50. 86Y. Nucl. Med. Commun., 2006, 27, 237-245. (Pubitemid 44391811)
51. Herzog, H.; Tellmann, L.; Scholten, B.; Coenen, H. H.; Qaim, S. M. Pet imaging problems with the non-standard positron emitters yttrium-86 and iodine-124. Q. J. Nucl. Med. Mol. Imag., 2008, 52, 159-165. (Pubitemid 351721936)
52. Buchholz, H. G.; Herzog, H.; Forster, G. J.; Reber, H.; Nickel, O.; Rosch, F.; Bartenstein, P. Pet imaging with yttrium-86: Comparison of phantom measurements acquired with different pet scanners before and after applying background subtraction. Eur. J. Nucl. Med. Mol. Imag., 2003, 30, 716-720. (Pubitemid 36612954)
53. Liu, X.; Laforest, R. Quantitative small animal pet imaging with nonconventional nuclides. Nucl. Med. Biol., 2009, 36, 551-559.
54. Philpott, G. W.; Schwarz, S. W.; Anderson, C. J.; Dehdashti, F.; Connett, J. M.; Zinn, K. R.; Meares, C. F.; Cutler, P. D.; Welch, M. J.; Siegel, B. A. Radioimmunopet: Detection of colorectal carcinoma with positron-emitting copper-64-labeled monoclonal antibody. J. Nucl. Med., 1995, 36, 1818-1824.
55. 89Zr-labeled monoclonal antibodies. J. Nucl. Med., 2003, 44, 1271-1281. (Pubitemid 39662684)
56. Meijs, W. E.; Haisma, H. J.; Van der Schors, R.; Wijbrandts, R.; Van den Oever, K.; Klok, R. P.; Pinedo, H. M.; Herscheid, J. D. A facile method for the labeling of proteins with zirconium isotopes. Nucl. Med. Biol., 1996, 23, 439-448. (Pubitemid 26233214)
57. Antunes, P.; Ginj, M.; Zhang, H.; Waser, B.; Baum, R. P.; Reubi, J. C.; Maecke, H. Are radiogallium-labelled dota-conjugated somatostatin analogues superior to those labelled with other radiometals? Eur. J. Nucl. Med. Mol. Imaging., 2007, 34, 982-993. (Pubitemid 46919547)
58. 68Ga-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on 111In-DTPA- octreotide scintigraphy. J. Nucl. Med., 2010, 51, 875-882.
59. Smith-Jones, P. M.; Solit, D. B.; Akhurst, T.; Afroze, F.; Rosen, N.; Larson, S. M. Imaging the pharmacodynamics of HER2 degradation in response to hsp90 inhibitors. Nature Biotech., 2004, 22, 701-706. (Pubitemid 38702826)